Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

J&J, GE Enter Alzheimer’s Early Detection Collaboration
Seeking Alpha
Sunday, December 5, 2010 - 11:57am
tags:
JNJ, Alzheimer's disease, GE Healthcare
Glaxo Finally Gives Up on Fountain of Youth Pill
Seeking Alpha
Sunday, December 5, 2010 - 11:55am
tags:
GSK, SRT501, Sirtris
Valeant, GSK Prepare for Approval of Anti-Epileptic Drug Despite Latest Delay
Seeking Alpha
Sunday, December 5, 2010 - 11:53am
tags:
Valeant Pharmaceuticals, GSK, epilepsy, Potiga
Advisory Votes Against Expanding Use of GSK’s, Merck’s Prostate Drugs: Biotech's Latest Tribulations
Seeking Alpha
Sunday, December 5, 2010 - 11:52am
tags:
GSK, Merck, Avodart, enlarged prostate, prostate cancer, Proscar, Orexigen, obesity, Contrave, Novartis, JNJ, Merck KGaA
80% Market Share In HIV Pharmaceutical Sector And Unappreciated Pipeline Make Gilead Sciences (GILD) A Contrarian Stock Pick From These Saint Louis Porfolio Managers
Yahoo/Wall Street Transcript
Sunday, December 5, 2010 - 11:48am
tags:
Gilead Sciences, HIV
Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Yahoo/BusinessWire
Sunday, December 5, 2010 - 11:47am
tags:
Seattle Genetics, Millennium, brentuximab vedotin, SGN-35, Hodgkin's lymphoma, Takeda
Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
Yahoo/BusinessWire
Sunday, December 5, 2010 - 11:43am
tags:
Rituxan, follicular lymphoma, Roche/Genentech, Biogen Idec
AEterna Zentaris: Three Near-Term Catalysts Will Continue to Boost Shares
Seeking Alpha
Sunday, December 5, 2010 - 11:41am
tags:
Aeterna Zentaris
U.S. Pharma: Latest Analyst Actions
Seeking Alpha
Sunday, December 5, 2010 - 11:35am
tags:
Seattle Genetics, Incyte, Biodel, Cadence Pharmaceuticals, NeurogesX, Metabolix, Gilead Sciences, Pfizer
Sun Pharma to delist troubled US subsidiary
Business Standard, India
Saturday, December 4, 2010 - 12:55pm
tags:
Sun Pharma
Neutral Short Term Pattern on Pfizer
Trader's Huddle
Saturday, December 4, 2010 - 12:42pm
tags:
Pfizer, investors
Vertex Pharmaceuticals Announces Webcast of its Presentation at the NASDAQ OMX Investor Conference
BusinessWire
Saturday, December 4, 2010 - 12:41pm
tags:
Vertex Pharmaceuticals
QR Pharma announces FDA clearance to begin trials related to Alzheimer compound
Behavioral Health Central
Saturday, December 4, 2010 - 12:40pm
tags:
QR Pharma, Alzheimer's disease, bisnorcymserine, butyrylcholinesterase inhibition
AstraZeneca raided by EU investigators amid collusion claims
Daily Mail, UK
Saturday, December 4, 2010 - 12:35pm
tags:
AstraZeneca, Nexium
FDA: Proposed Weight Loss Drug Contrave Raises Blood Pressure
WSJ
Saturday, December 4, 2010 - 12:33pm
tags:
Takeda, Contrave, weight loss, obesity. Orexigen Therapeutics
More Than 1,000 Drug Patents Expiring During the Next Two Years: PharmaLive Special Reports
PharmaLive
Saturday, December 4, 2010 - 12:31pm
tags:
patents
Teva Pharmaceutical Industries Downward Momentum Looks to Continue (TEVA)
Benzinga
Saturday, December 4, 2010 - 12:30pm
tags:
Teva Pharmaceuticals, investors
How Cheap Is Amgen's Stock by the Numbers?
Motley Fool
Saturday, December 4, 2010 - 12:20pm
tags:
Amgen, investors
Pfizer Plans $75 Million Fund to Address Shareholder Suits
NY Times
Saturday, December 4, 2010 - 12:19pm
tags:
Pfizer, investors, lawsuits
Setback for Valeant Epilepsy Drug
Yahoo/Zacks
Saturday, December 4, 2010 - 12:18pm
tags:
Valeant Pharmaceuticals, epilepsy, ezogabine, GSK

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.